PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context” or the "Company”) (Nasdaq: CNTX), a ...
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...
PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...
GlobalData on MSN13d
Context doses first subject in Phase I cancer trial of CTIM-76Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting gynaecologic and testicular cancers.
About Context Therapeutics ® Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is ...
Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...
Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or CLDN6, x CD3 T cell engaging bispecific antibody.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback